GlassScriptPhysician profile
Ching-Min Lin
NPI 1407498538
$2,198.63
in general payments reported to CMS, 2019-2025
20 companies · $58.95 in 2025
The $58.95 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $979 · 2022: $672 · 2023: $324 · 2024: $165 · 2025: $58.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.38 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $395.72 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $311.14 | 2022-2024 | |
| Amarin Pharma, INC. | $307.21 | 2021-2023 | |
| Abbvie INC. | $198.03 | 2021-2023 | |
| Esperion Therapeutics, INC. | $191.69 | 2021-2023 | Nexletol |
| Opko Pharmaceuticals, LLC | $164.87 | 2021-2023 | Rayaldee |
| Lilly USA, LLC | $140.94 | 2021-2023 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $98.71 | 2021-2025 | Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $84.32 | 2021-2023 | Farxiga |
| Redhill Biopharma INC. | $39.87 | 2022-2023 | Talicia |
| Mallinckrodt Hospital Products INC. | $34.42 | 2021 | |
| Seqirus USA INC | $34.33 | 2021-2022 | |
| Axsome Therapeutics, INC. | $34.28 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.14 | 2022 | |
| Amgen INC. | $24.35 | 2023 | Repatha, Otezla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $22.97 | 2021 | |
| Calliditas Therapeutics US INC. | $22.71 | 2023 | Tarpeyo |
| Ibsa Pharma INC. | $22.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.95 | 2021 | |
| Astellas Pharma US INC | $20.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching-Min Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.